Predictive approaches to heterogeneous treatment effects: a systematic review
暂无分享,去创建一个
John B. Wong | Ewout W. Steyerberg | Gowri Raman | David M. Kent | Peter R. Rijnbeek | Jessica K. Paulus | Alexandros Rekkas | David van Klaveren | D. van Klaveren | E. Steyerberg | J. Paulus | D. Kent | G. Raman | John B. Wong | P. Rijnbeek | A. Rekkas
[1] Helena Chmura Kraemer,et al. Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach , 2013, Statistics in medicine.
[2] Richard D Riley,et al. Explicit inclusion of treatment in prognostic modeling was recommended in observational and randomized settings. , 2016, Journal of clinical epidemiology.
[3] Eric B. Laber,et al. Inference about the expected performance of a data-driven dynamic treatment regime , 2014, Clinical trials.
[4] Max Welling,et al. Causal Effect Inference with Deep Latent-Variable Models , 2017, NIPS 2017.
[5] Yvonne Vergouwe,et al. Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions. , 2015, Journal of clinical epidemiology.
[6] J. Berger,et al. A Bayesian Approach to Subgroup Identification , 2014, Journal of biopharmaceutical statistics.
[7] David M. Kent,et al. Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation , 2016, Circulation. Heart failure.
[8] B. Freidlin,et al. Statistical and practical considerations for clinical evaluation of predictive biomarkers. , 2013, Journal of the National Cancer Institute.
[9] Daniel J Sargent,et al. The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. , 2015, Journal of the National Cancer Institute.
[10] Holly Janes,et al. Assessing Treatment‐Selection Markers using a Potential Outcomes Framework , 2012, Biometrics.
[11] Wenting Cheng,et al. Reader reaction to “A robust method for estimating optimal treatment regimes” by Zhang et al. (2012) , 2015, Biometrics.
[12] Ravi Varadhan,et al. A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. , 2013, Journal of clinical epidemiology.
[13] Michael J. Pencina,et al. Use of Open Access Platforms for Clinical Trial Data. , 2016, JAMA.
[14] Lacey Gunter,et al. Variable Selection for Qualitative Interactions in Personalized Medicine While Controlling the Family-Wise Error Rate , 2011, Journal of biopharmaceutical statistics.
[15] Ellen Frank,et al. A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. , 2013, JAMA psychiatry.
[16] Harlan M Krumholz,et al. Overview and experience of the YODA Project with clinical trial data sharing after 5 years , 2018, Scientific Data.
[17] Mark J van der Laan,et al. Evaluating the impact of treating the optimal subgroup , 2016, Statistical methods in medical research.
[18] Matthew M. Chingos,et al. The Review of Economics and Statistics , 2018 .
[19] D A Follmann,et al. A Multivariate Test of Interaction for Use in Clinical Trials , 1999, Biometrics.
[20] Gordon H Guyatt,et al. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. , 2002, International journal of epidemiology.
[21] Menggang Yu,et al. Regularized outcome weighted subgroup identification for differential treatment effects , 2015, Biometrics.
[22] Sanjay Basu,et al. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials , 2017, PLoS medicine.
[23] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[24] R. Varadhan,et al. Bedside Optic Nerve Ultrasonography for Diagnosing Increased Intracranial Pressure , 2019, Annals of Internal Medicine.
[25] Andrew J Vickers,et al. Method for evaluating prediction models that apply the results of randomized trials to individual patients , 2007, Trials.
[26] Ewout Steyerberg,et al. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects , 2018, British Medical Journal.
[27] Lee-Jen Wei,et al. Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. , 2015, Biostatistics.
[28] David M Kent,et al. Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH) , 2015, BJU international.
[29] Antonio Colombo,et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.
[30] Mark J van der Laan,et al. Targeted Learning of the Mean Outcome under an Optimal Dynamic Treatment Rule , 2015, Journal of causal inference.
[31] James F Burke,et al. Implications of Heterogeneity of Treatment Effect for Reporting and Analysis of Randomized Trials in Critical Care. , 2015, American journal of respiratory and critical care medicine.
[32] Robert Tibshirani,et al. A comparison of methods for model selection when estimating individual treatment effects , 2018, 1804.05146.
[33] M. J. van der Laan,et al. STATISTICAL INFERENCE FOR THE MEAN OUTCOME UNDER A POSSIBLY NON-UNIQUE OPTIMAL TREATMENT STRATEGY. , 2016, Annals of statistics.
[34] Ewout W Steyerberg,et al. Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting. , 2019, Journal of clinical epidemiology.
[35] F E Harrell,et al. Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. , 1997, American heart journal.
[36] Sören R. Künzel,et al. Metalearners for estimating heterogeneous treatment effects using machine learning , 2017, Proceedings of the National Academy of Sciences.
[37] Federico Rotolo,et al. Identification of biomarker‐by‐treatment interactions in randomized clinical trials with survival outcomes and high‐dimensional spaces , 2016, Biometrical journal. Biometrische Zeitschrift.
[38] P. Rothwell,et al. Can overall results of clinical trials be applied to all patients? , 1995, The Lancet.
[39] L. Caplan,et al. Evidence based medicine: concerns of a clinical neurologist , 2001, Journal of neurology, neurosurgery, and psychiatry.
[40] Niko Kaciroti,et al. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data. , 2015, Biostatistics.
[41] Issa J Dahabreh,et al. Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. , 2016, International journal of epidemiology.
[42] Eva Petkova,et al. Generated effect modifiers (GEM's) in randomized clinical trials. , 2017, Biostatistics.
[43] Ewout W Steyerberg,et al. Estimating treatment effects for individual patients based on the results of randomised clinical trials , 2011, BMJ : British Medical Journal.
[44] H. Weisberg,et al. Post hoc subgroups in clinical trials: Anathema or analytics? , 2015, Clinical trials.
[45] David M. Kent,et al. Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical Trials , 2014, Circulation. Cardiovascular quality and outcomes.
[46] David M Kent,et al. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. , 2007, JAMA.
[47] Discussion of “Dynamic treatment regimes: Technical challenges and applications” , 2014 .
[48] Eric B. Laber,et al. A Robust Method for Estimating Optimal Treatment Regimes , 2012, Biometrics.
[49] Lu Tian,et al. A Simple Method for Detecting Interactions between a Treatment and a Large Number of Covariates , 2012, 1212.2995.
[50] Joseph S. Ross,et al. Clinical research data sharing: what an open science world means for researchers involved in evidence synthesis , 2016, Systematic Reviews.
[51] Ewout W Steyerberg,et al. The proposed 'concordance-statistic for benefit' provided a useful metric when modeling heterogeneous treatment effects. , 2018, Journal of clinical epidemiology.
[52] S. Murphy,et al. PERFORMANCE GUARANTEES FOR INDIVIDUALIZED TREATMENT RULES. , 2011, Annals of statistics.
[53] E. Steyerberg. Clinical Prediction Models , 2008, Statistics for Biology and Health.
[54] Lu Tian,et al. Effectively Selecting a Target Population for a Future Comparative Study , 2013, Journal of the American Statistical Association.
[55] James A Hanley,et al. Profile-specific survival estimates: Making reports of clinical trials more patient-relevant , 2008, Clinical trials.
[56] L. Tian,et al. Analysis of randomized comparative clinical trial data for personalized treatment selections. , 2011, Biostatistics.
[57] Debashis Ghosh,et al. Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer , 2009, Biometrics.
[58] Jennifer L Krull,et al. Advancing Personalized Medicine: Application of a Novel Statistical Method to Identify Treatment Moderators in the Coordinated Anxiety Learning and Management Study. , 2017, Behavior therapy.
[59] Min Zhang,et al. Estimating optimal treatment regimes from a classification perspective , 2012, Stat.
[60] S. Athey,et al. Generalized random forests , 2016, The Annals of Statistics.
[61] Holly Janes,et al. Measuring the Performance of Markers for Guiding Treatment Decisions , 2011, Annals of Internal Medicine.
[62] David M Kent,et al. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis , 2006, BMC medical research methodology.
[63] Trevor Hastie,et al. Some methods for heterogeneous treatment effect estimation in high dimensions , 2017, Statistics in medicine.
[64] Donglin Zeng,et al. Estimating Individualized Treatment Rules Using Outcome Weighted Learning , 2012, Journal of the American Statistical Association.
[65] Jeremy B Sussman,et al. Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program , 2015, BMJ : British Medical Journal.
[66] Stephanie Kovalchik,et al. Assessing heterogeneity of treatment effect in a clinical trial with the proportional interactions model , 2013, Statistics in medicine.
[67] David M Kent,et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal , 2010, Trials.
[68] Eric B. Laber,et al. Doubly Robust Learning for Estimating Individualized Treatment with Censored Data. , 2015, Biometrika.